Solana Company

Welcome to the Healy's Medical Technologies Q3 2021 Earnings Conference Call. My name is Richard and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. During the question and answer session, if you have a question, please press 01 on your touchstone phone. As a reminder, the conference is being recorded. I'll now turn the call over to Judy Clemente. You may begin.

Thank you, operator. Welcome to the first quarter 2022 earnings conference call for Helios Medical Technologies. This is Judy DiClemente of Insight Communications, Investor Relations for Helios. With me on today's call are Dane Andrews, Helios Medical's President and Chief Executive Officer, Jeff Mathisen, Chief Financial Officer, Antonella Fabit-Van Pelt, Chief Medical Officer, and Fred Fantasia, Vice President, Sales and Marketing, North America. At this time, all participants have been placed in a listen-only mode. Please note that this call is being recorded and access to the webcast can be obtained through the investor section of the Helios website at www.heliosmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the risk factor sections of our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Such factors may be updated from time to time in our other filings with the SEC, which are available on our website. All statements made during this call are as of May 12, 2022. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise, except as required by law. I would now like to turn the call over to Dane Andrews, President and Chief Executive Officer of Helios.

Thanks, Judy. Welcome everyone to Helios Medical's first quarter 2022 earnings conference call. This was the first quarter that PONS therapy was commercially available in the United States and we are already seeing an enthusiastic response. As a reminder, PONS stands for Portable Neuromodulation Stimulator and it is currently indicated in the United States for short-term treatment of gait deficit due to mild to moderate symptoms of MS and is designed to be used in conjunction with a supervised therapeutic exercise program. Until now, treatment options have been limited, but 14 weeks of PONS therapy has demonstrated significant gait improvement as compared to physical therapy alone. PONS is both safe and effective And the launch is an important development, not only for the company, but also for the over 1 million patients in the U.S. battling MS. Before we provide more color on the rollout, I wanted to introduce to you Dr. Antonella Favit-Van Pelt, MD, PhD, a board-certified neurologist and Helios Chief Medical Officer who will go into greater detail about PONS therapy. Antonella?